Inhibitory receptor agonists: Emerging strategies in immune modulation
Journal of Experimental Medicine · 06.04.2026 · 223 (4)
DOI: 10.1084/jem.20241217 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Experimental Medicine, online erschienen am 31.03.2026. Verfasst von Kieran R Adam und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. Hauptthemen laut MEDLINE: Receptors, Immunologic. Die Arbeit nennt 314 Literaturangaben. Gefördert von: NIH HHS, Melanoma Research Alliance, National Multiple Sclerosis Society.
Abstract (Originalsprache)
Inhibitory receptors (IRs) such as CTLA-4, PD-1, LAG3, TIM-3, and TIGIT are critical regulators of immune homeostasis, functioning to restrain excessive immune activation and prevent autoimmunity. While the blockade of IRs has transformed cancer immunotherapy by reinvigorating antitumor T cell responses, emerging strategies aim to harness the immunosuppressive potential of these receptors for treating autoimmune and inflammatory diseases. Agonistic antibodies that activate IR signaling have demonstrated promising results in preclinical models by promoting immune tolerance and suppressing pathological effector T cell functions. This review highlights recent progress in the development of agonistic IR-targeted therapies, examining their mechanisms of action, therapeutic efficacy, and the translational challenges that must be addressed to bring these innovative approaches into clinical practice for the management of autoimmunity and inflammatory disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
- Program in Microbiology and Immunology, University of Pittsburgh School of Medicine , Pittsburgh, PA, USA.
- Tumor Microenvironment Center, University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center , Pittsburgh, PA, USA.
- Gene Lay Institute of Immunology and Inflammation, Brigham and Women's Hospital, Massachusetts General Hospital and Harvard Medical School , Boston, MA, USA.
- Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School , Boston, MA, USA.
- Broad Institute of MIT and Harvard , Cambridge, MA, USA.
ORCID-Profile: Kieran R Adam, Aamir Suhail, Vijay K Kuchroo, Dario A A Vignali
Förderung
- NIH HHS
- Melanoma Research Alliance
- National Multiple Sclerosis Society
- National institutes of Health
Zitieren
APA
Adam, K. R., Suhail, A., Kuchroo, V. K., & Vignali, D. A. A. (2026). Inhibitory receptor agonists: Emerging strategies in immune modulation. Journal of Experimental Medicine, 223(4). https://doi.org/10.1084/jem.20241217
Vancouver
Adam KR, Suhail A, Kuchroo VK, Vignali DAA. Inhibitory receptor agonists: Emerging strategies in immune modulation. Journal of Experimental Medicine. 2026;223(4). doi:10.1084/jem.20241217
BibTeX
@article{Adam2026,
author = {Adam, Kieran R and Suhail, Aamir and Kuchroo, Vijay K and Vignali, Dario A A},
title = {Inhibitory receptor agonists: Emerging strategies in immune modulation},
journal = {Journal of Experimental Medicine},
year = {2026},
volume = {223},
number = {4},
doi = {10.1084/jem.20241217}
}
EUVIMED